Design Therapeutics shares Phase 1/2 data in Friedreich ataxia; Vincentage Pharma, a new China obesity player, emerges with Phase 3 data; Roche’s Tecentriq secures another US approval for bladder cancer; Enhertu wins label expansion for two early breast cancer indications